SEC Form 4 · accession 0001445064-15-000014
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Trudeau
Officer — President & CEO · Director
Period of report
Jan 2, 2015
Accepted (ET)
Jan 6, 2015 · 5:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 2, 2015 | A | 15,986 | $0.00 | A | 156,404 | D | |
| Ordinary Shares | Jan 2, 2015 | F | 1,227 | $96.96 | D | 155,177 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Options (Right to Buy)F2 | $96.96 | Jan 2, 2015 | A | 108,014 | A | Jan 2, 2016 | Jan 2, 2025 | Ordinary Shares | 108,014 | 108,014 | D |
Explanation of responses
- F1The restricted stock units vest in four equal annual installments beginning January 2, 2016.
- F2The options vest in four equal annual installments beginning January 2, 2016.